via Wikipedia
Researchers from Genethon, the AFM-Téléthon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy. Indeed, after injecting microdystrophin (a “shortened” version of the dystrophin gene) via a drug vector, the researchers managed to restore muscle strength and stabilise the clinical symptoms in dogs naturally affected by Duchenne muscular dystrophy.
This work published in Nature Communications has been achieved thanks to the donations of the French Téléthon.
Teams at Genethon developed, in collaboration with a team at Royal Holloway University of London led by Pr. Dickson, and produced, a gene therapy drug combining an AAV-type viral vector with a shortened version of the dystrophin gene (approximately 4,000 base pairs), allowing the production of a functional protein. Dr Le Guiner’s team tested this innovative treatment in 12 dogs naturally affected by Duchenne muscular dystrophy. By injecting this microdystrophin intravenously, and hence into the whole body of the dogs, the researchers observed that dystrophin expression returned to a high level, and muscle function was significantly restored, with stabilisation of the clinical symptoms observed for over 2 years following injection of the drug. No immunosuppressive treatment was administered beforehand, and no sideeffects were observed.
Some Golden Retrievers develop Duchenne muscular dystrophy naturally. The successful treatment of these dogs, which show the same clinical symptoms as children with this disease, and are of a similar weight, is a decisive step toward developing the same treatment in children. “This preclinical study demonstrates the safety and efficacy of microdystrophin, and makes it possible to consider developing a clinical trial in patients. Indeed, this is the first time that it has been possible to treat the whole body of a large sized animal with this protein. Moreover, this innovative approach allows treatment of all patients with Duchenne muscular dystrophy, regardless of the genetic mutation responsible,” says Caroline Le Guiner, the main author of this study.
Learn more: Gene therapy: Microdystrophin restores muscle strength in Duchenne muscular dystrophy
The Latest on: Duchenne muscular dystrophy
- Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Billings Clinicon August 4, 2022 at 7:45 am
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced the expansion of their renowned Certified Duchenne Care ...
- Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophyon August 4, 2022 at 5:35 am
The natural history study will generate data to further the ongoing efforts of the myotonic dystrophy research community to understand disease progression and identify potential clinical outcome ...
- Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlightson August 4, 2022 at 4:30 am
Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Dyne ...
- Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analystson August 3, 2022 at 11:20 am
Sarepta Therapeutics Inc (NASDAQ: SRPT) reported above-consensus 2Q FY22 product sales of $211 million and provided more details on the path forward for SRP-9001 gene therapy for Duchenne muscular ...
- Oxford-Harrington Rare Disease Centre to Advance Novel Treatment for Duchenne Muscular Dystrophyon August 2, 2022 at 7:16 am
New therapy seeks to protect from rare muscle-wasting disorder OXFORD, England and CLEVELAND, Aug. 2, 2022 /PRNewswire/ -- The Oxford-Harrington ...
- More drama ahead: Sarepta plans to file for accelerated Duchenne approval, with adcomm a 'near certainty'on July 29, 2022 at 8:53 am
While Sarepta has three antisense oligonucleotide therapies approved — albeit not without controversy — for Duchenne muscular dystrophy, it has been working on a long-term treatment in the form of a ...
- Sarepta to ask FDA for accelerated approval of Duchenne gene therapyon July 29, 2022 at 8:46 am
After discussions with the FDA, the biotech aims to submit an application this fall — sooner than expected and ahead of a Phase 3 study that’s now ongoing.
- Sarepta looks for quick approval for Duchenne muscular dystrophy gene therapy treatmenton July 29, 2022 at 7:13 am
Sarepta is looking for accelerated approval for SRP-9001 to treat ambulant individuals with Duchenne muscular dystrophy.
- Sarepta to seek early FDA approval for gene therapy to treat Duchenne muscular dystrophyon July 29, 2022 at 6:23 am
Sarepta Therapeutics said that it intends to file an earlier-than-expected application to U.S. regulators, seeking approval for a gene therapy to treat Duchenne muscular dystrophy.
- Global Duchenne Muscular Dystrophy Drugs Market Size, Share Remuneration to Surge At 28.9% CAGR Through 2026on July 11, 2022 at 3:36 am
Jul 11, 2022 (Market Insight Reports) -- The report Duchenne Muscular Dystrophy Drugs Market Size and Analysis maintains enhanced dynamics and is overshadowed by a top player across the globe.
via Google News and Bing News